Pharmacological inhibition of Bcl2 family proteins was initially considered an effective strategy in cancer therapy [7], and several Bcl2 protein inhibitors, such as ABT-199, ABT-263, ABT-737, and AT-101, have been developed as cancer therapeutics [7]. The gene discussed is BCL2; the disease is cancer.